• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

FDA ex­e­cutes a 180 on Ther­a­peu­tic­sMD ther­a­py, hand­ing it an OK — and stok­ing con­cerns about po­lit­i­cal in­flu­ence

7 years ago
Pharma

As­traZeneca writes off its sec­ond piv­otal COPD tri­al for Fasen­ra, killing ex­pan­sion plans

7 years ago
R&D

Rac­ing to grab mar­ket share in di­a­betes, No­vo touts its oral semaglu­tide win over Jar­diance in PhI­I­Ia tri­al

7 years ago
R&D

Astel­las wins pri­or­i­ty re­view for AML drug; Take­da share­hold­ers re­volt against $62B Shire deal

7 years ago
News Briefing

Arc­turus' ex-CEO tri­umphs, oust­ing board that oust­ed him

7 years ago
People

With $460B in bor­row­ing ca­pac­i­ty, will any of the Big-20 bio­phar­mas go af­ter one of the top-5 takeover tar­gets?

7 years ago
Deals

Af­ter sink­ing $300M in­to SF fund last year, Hong Kong con­glom­er­ate launch­es $100M arm in Shang­hai

7 years ago
Financing
China

Top re­search ex­ecs from Te­va, Al­ler­gan re­cruit­ed to help lead Ax­o­vant out of the R&D waste­land

7 years ago
People
R&D

AS­CO loom­ing, Loxo, Bay­er line up a quick shot at FDA OK for their ground­break­ing ap­proach to can­cer ther­a­py

7 years ago
Pharma

Ei­dos, Avro­bio shoot for $201M as biotech IPOs con­tin­ue to roll for­ward on Nas­daq

7 years ago
Financing

Gen­mab takes a hit af­ter J&J sounds re­treat on can­cer com­bos, as pa­tient deaths force re­search­es to scrap tri­als

7 years ago
R&D

Roche's Tecen­triq scores again on a piv­otal front­line lung can­cer tri­al, po­si­tion­ing them against Mer­ck, ...

7 years ago
R&D

CRI re­port tracks ex­plo­sive growth of cell ther­a­pies in the glob­al pipeline, as Chi­na re­searchers mus­cle to­ward the ...

7 years ago
China
Cell/Gene Tx

Ex-Gilead R&D chief Bischof­berg­er starts over as CEO of Kro­nos Bio; Sue Ma­ho­ny steps down from Lil­ly On­col­o­gy

7 years ago
Peer Review

Kezar and Xeris file for IPOs, join­ing May's march to the pub­lic mar­kets

7 years ago
Financing

Af­ter some sting­ing set­backs, a top an­a­lyst ques­tions the high fail­ure rate for Cel­gene's drug pipeline

7 years ago
R&D

Those open of­fices bio­phar­ma ex­ecs love so much? Most staffers hate them with a pas­sion

7 years ago
Pharma

As­traZeneca caps its big win in lung can­cer with pos­i­tive sur­vival da­ta for Imfinzi — and what a re­lief it is

7 years ago
R&D

Bio­Marin gets its shot at an­oth­er block­buster as FDA OKs rare dis­ease drug peg­valiase

7 years ago
Pharma

Ma­gen­ta Ther­a­peu­tics un­veils plans to raise $100M in IPO weeks af­ter a crossover round

7 years ago
Financing

Re­cro shares tank on FDA’s CRL; Prothena ax­es more than half of staff; No­vo inks $200M deal with Epi­gen

7 years ago
News Briefing

Mer­ck da­ta and a tum­bling stock price cost Ar­mo's in­vestors $320M-plus in Eli Lil­ly buy­out

7 years ago
Deals

Brad Lon­car­'s AS­CO18 pre­view: Past AS­COs point to the top drugs that will soon el­bow for the Os­cars of can­cer R&D

7 years ago
Biotech Voices

Rock­well's CEO re­fus­es to be fired, kick­ing up brawl with board that halts the com­pa­ny's stock

7 years ago
People
First page Previous page 1024102510261027102810291030 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.